Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

This study has been completed.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Gemin X ) Identifier:
First received: May 20, 2008
Last updated: July 19, 2016
Last verified: July 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2011
  Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: August 27, 2013